Quarterly report · Q1
4564.TEDINET S100OW16
Period2022-04-01 → 2022-06-30
Filed2022-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 30
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥386m | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥93m | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | −¥307m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥572m | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | −¥314m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥572m | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥277m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥535m | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥278m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥535m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥278m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥535m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥2.0bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥2.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥3.6bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥373m | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥705m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.5bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-1.44 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 79.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.6% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 29
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥55,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥55,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥101m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥380m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥380m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥9m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥55,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥215m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥386m |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥386m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥55,000 |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | −¥206m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥8m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥8m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥107m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥96m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥87m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥8m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥33m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥62,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥431m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥102m |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥93m |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥8m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | −¥464m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 313
| Item | Context | Value | Unit |
|---|---|---|---|
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-06-30 | |
| Type of current period | FilingDateInstant | Q1 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Material matters relating to going concern etc business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所 グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |